enGene's Losses Double Amid R&D Surge, Cash Dwindles

TL;DR

**enGene is burning cash at an alarming rate, and without new funding, this biotech's future is highly uncertain.**

AI Summary

enGene Holdings Inc. (ENGNW) reported a significant increase in net loss and operating expenses for the nine months ended July 31, 2025. The net loss surged to $79.4 million, a substantial increase from $39.8 million in the same period last year. This was primarily driven by a doubling of research and development expenses to $62.8 million from $27.0 million, reflecting intensified efforts in its DDX gene delivery platform and detalimogene clinical trials. General and administrative expenses also rose to $20.9 million from $17.8 million. The company's cash and cash equivalents decreased sharply to $32.6 million as of July 31, 2025, from $173.0 million at October 31, 2024, with net cash used in operating activities reaching $74.3 million. Despite the cash burn, marketable securities (short-term) increased to $169.3 million from $65.3 million, indicating a shift in asset allocation. The company explicitly states it has incurred significant operating losses and negative cash flows since inception and anticipates these will continue, raising substantial doubt about its ability to continue as a going concern within one year without additional funding.

Why It Matters

enGene's escalating net loss and significant cash burn are critical for investors, signaling a heightened need for future capital raises which could dilute existing shareholders. The substantial increase in R&D spending, particularly on detalimogene, indicates aggressive pursuit of its lead product, but also amplifies financial risk. For employees, continued losses and going concern warnings could create job insecurity. Customers and the broader market are impacted by the uncertainty surrounding the development of new genetic medicines, as enGene's financial health directly affects its ability to bring innovative treatments to market, especially in a competitive biotech landscape.

Risk Assessment

Risk Level: high — The company explicitly states it has incurred a net loss of $79.4 million and negative cash flows from operating activities of $74.3 million for the nine months ended July 31, 2025, and anticipates these losses will continue. This, combined with a sharp decline in cash and cash equivalents from $173.0 million to $32.6 million, raises "substantial doubt about the Company's ability to continue as a going concern within one year." This direct disclosure of going concern risk, coupled with significant cash depletion, indicates a high-risk profile.

Analyst Insight

Investors should exercise extreme caution and consider reducing exposure to ENGNW given the explicit going concern warning and rapid cash burn. Prospective investors should await clear evidence of successful clinical trial outcomes and a robust financing plan before considering an investment. Monitor future filings closely for updates on funding and clinical milestones for detalimogene.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$79.4M

eps

N/A

gross Margin

N/A

cash Position

$32.6M

revenue Growth

N/A

Key Numbers

• $79.4M — Net loss for nine months ended July 31, 2025 (Increased from $39.8M in prior year, indicating doubling of losses.)
• $62.8M — Research and development expenses for nine months ended July 31, 2025 (Increased from $27.0M, showing significant investment in product development.)
• $32.6M — Cash and cash equivalents as of July 31, 2025 (Decreased from $173.0M at October 31, 2024, highlighting rapid cash depletion.)
• $74.3M — Net cash used in operating activities for nine months ended July 31, 2025 (Increased from $28.7M in prior year, reflecting accelerated operational burn.)
• $169.3M — Marketable securities - short term as of July 31, 2025 (Increased from $65.3M, suggesting a shift in liquidity management.)
• 51,191,771 — Common Shares outstanding as of September 10, 2025 (Reflects total shares outstanding.)

Key Players & Entities

• enGene Holdings Inc. (company) — registrant
• The Nasdaq Stock Market LLC (regulator) — exchange for ENGN and ENGNW
• U.S. Food and Drug Administration (regulator) — potential approval body for detalimogene
• European Medicines Agency (regulator) — potential approval body for detalimogene
• DDX gene delivery platform (company) — proprietary technology
• detalimogene voraplasmid (company) — lead product candidate
• Chief Executive Officer (person) — chief operating decision-maker
• Bloomberg (company) — publisher
• SEC (regulator) — filing oversight

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has incurred significant operating losses and negative cash flows since inception and anticipates these will continue. This raises substantial doubt about its ability to continue as a going concern within one year without additional funding, as evidenced by the decrease in cash and cash equivalents to $32.6 million from $173.0 million.
• Increased R&D Spending [medium — operational]: Research and development expenses more than doubled to $62.8 million for the nine months ended July 31, 2025, from $27.0 million in the prior year. This significant increase reflects intensified efforts in its DDX gene delivery platform and detalimogene clinical trials, impacting cash burn.
• Rising G&A Expenses [medium — operational]: General and administrative expenses increased to $20.9 million for the nine months ended July 31, 2025, from $17.8 million in the same period last year. This rise contributes to the overall increase in operating expenses and cash outflow.
• Accelerated Cash Burn [high — financial]: Net cash used in operating activities surged to $74.3 million for the nine months ended July 31, 2025, compared to $28.7 million in the prior year. This accelerated burn rate, coupled with a reduced cash position, heightens liquidity concerns.

Industry Context

enGene operates in the highly competitive and rapidly evolving gene therapy sector. This industry is characterized by significant R&D investment, long development timelines, and substantial regulatory hurdles. Companies in this space often face intense competition for talent, capital, and market share, with a focus on novel delivery platforms and therapeutic candidates for unmet medical needs.

Regulatory Implications

As a gene therapy company, enGene is subject to stringent regulatory oversight from bodies like the FDA. Clinical trial failures, delays in regulatory approvals, or changes in regulatory requirements could significantly impact its ability to bring products to market and generate revenue. The company's reliance on its DDX platform and detalimogene trials means regulatory success is paramount.

What Investors Should Do

1. Monitor cash burn rate closely: The significant increase in net loss and operating cash outflows necessitates close monitoring of the company's remaining cash runway and its ability to secure additional funding.
2. Evaluate clinical trial progress: Investor focus should be on the progress and outcomes of the detalimogene clinical trials, as these are key value drivers for enGene.
3. Assess funding strategy: Understand the company's plans for raising additional capital, including potential equity offerings, debt financing, or strategic partnerships, given the going concern warning.

Glossary

DDX gene delivery platform

A proprietary technology developed by enGene for delivering genetic material into cells, likely for therapeutic purposes. (This is a core area of investment and development for enGene, driving significant R&D expenses and future revenue potential.)

detalimogene

A specific gene therapy candidate being developed by enGene, likely for cancer treatment, which is currently in clinical trials. (Clinical trial progress and success for detalimogene are critical to the company's future prospects and valuation.)

Going Concern

An accounting principle that assumes a company will continue to operate for the foreseeable future. If there is substantial doubt about this, it must be disclosed. (The company explicitly states substantial doubt about its ability to continue as a going concern, indicating significant financial distress and the need for immediate funding.)

Marketable Securities

Investments that are readily convertible to cash, such as stocks, bonds, and other financial instruments. (The significant increase in short-term marketable securities suggests a strategic shift in how the company is managing its remaining liquidity, potentially to preserve capital or generate some return.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, enGene Holdings Inc. has experienced a dramatic increase in its net loss, nearly doubling to $79.4 million. This is primarily driven by a substantial escalation in R&D expenses, which more than doubled to $62.8 million, reflecting increased investment in its core platforms and clinical trials. Concurrently, the company's cash position has significantly diminished, falling from $173.0 million to $32.6 million, while operating cash burn has accelerated, with net cash used in operations rising from $28.7 million to $74.3 million. This indicates a worsening financial condition and increased reliance on external funding.

Key Financial Figures

• $11.50 — e Common Share, at an exercise price of $11.50 per share ENGNW The Nasdaq Stock Ma

Filing Documents

• engn-20250731.htm (10-Q) — 2312KB
• engn-ex10_6.htm (EX-10.6) — 130KB
• engn-ex10_7.htm (EX-10.7) — 132KB
• engn-ex31_1.htm (EX-31.1) — 22KB
• engn-ex31_2.htm (EX-31.2) — 22KB
• engn-ex32_1.htm (EX-32.1) — 12KB
• engn-ex32_2.htm (EX-32.2) — 12KB
• 0000950170-25-114224.txt ( ) — 10170KB
• engn-20250731.xsd (EX-101.SCH) — 1556KB
• engn-20250731_htm.xml (XML) — 1830KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 4 Condensed Consolidated Balance Sheets as of July 31, 2025 and October 31, 2024 4 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended July 31, 2025 and 2024 5 Condensed Consolidated Statements of Shareholders' Equity for the Three and Nine Months Ended July 31, 2025 and 2024 6 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended July 31, 2025 and 2024 7 Notes to the Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 31 Item 4.

Controls and Procedures

Controls and Procedures 31 PART II. OTHER INFORMATION 33 Item 1.

Legal Proceedings

Legal Proceedings 33 Item 1A.

Risk Factors

Risk Factors 33 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 33 Item 3. Defaults Upon Senior Securities. 33 Item 4. Mine Safety Disclosures. 33 Item 5. Other Information 33 Item 6. Exhibits 33

Signatures

Signatures 35 1 SPECIAL NOT E REGARDING FORWARD-LOOKING STATEMENTS Certain statements in this Quarterly Report on Form 10-Q (this "Quarterly Report") may constitute "forward-looking statements" within the meaning of U.S. securities laws and "forward-looking information" within the meaning of Canadian securities laws (collectively, "forward-looking statements"). Our forward-looking statements include, but are not limited to, statements regarding management teams' expectations, hopes, beliefs, intentions, goals or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "appear," "approximate," "believe," "continue," "could," "estimate," "expect," "foresee," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "would" and similar expressions (or the negative version of such words or expressions) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this Quarterly Report may include, for example, statements about: our financial performance including financial projections and business metrics and any underlying assumptions thereunder; our ability to maintain the listing of the Company's common shares ("Common Shares") and warrants to purchase Common Shares ("Warrants") on The Nasdaq Global Market ("Nasdaq") or another national securities exchange; our success in recruiting and retaining, or changes required in, officers, key personnel or directors; our plans and ability to execute product development, manufacturing process development, preclinical and clinical development efforts successfully and on anticipated timelines; our ability to design, initiate and successfully complete clinical trials and other studies

—FIN ANCIAL INFORMATION

PART I—FIN ANCIAL INFORMATION Ite m 1. Financial Statements. ENGENE HOLDINGS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) (Unaudited) July 31, 2025 October 31, 2024 Assets Current assets: Cash and cash equivalents $ 32,623 $ 173,004 Marketable securities - short term 169,290 65,328 Restricted investments 72 72 Investment tax credits receivable 709 332 Prepaid and other current assets 8,618 8,626 Total current assets 211,312 247,362 Marketable securities - long term 23,011 59,527 Property and equipment, net 1,879 1,169 Operating lease right of use asset 7,969 1,741 Other assets 1,379 1,374 Total assets $ 245,550 $ 311,173 Liabilities and shareholders' equity Current liabilities: Accounts payable $ 2,384 $ 1,411 Accrued expenses and other current liabilities 11,117 12,128 Operating lease liabilities, current 1,527 423 Current portion of note payable 5,412 699 Total current liabilities 20,440 14,661 Note payable, net of current portion 17,706 22,473 Operating lease liabilities, net of current portion 6,732 1,427 Total liabilities 44,878 38,561 Shareholders' equity: Common shares, no par value; unlimited shares authorized, 51,105,807 and 50,976,676 shares issued and outstanding as of July 31, 2025 and October 31, 2024, respectively. 510,164 509,811 Additional paid-in capital 25,869 18,950 Accumulated other comprehensive loss ( 1,209 ) ( 1,419 ) Accumulated deficit ( 334,152 ) ( 254,730 ) Total shareholders' equity 200,672 272,612 Total liabilities and shareholders' equity $ 245,550 $ 311,173 The accompanying notes are an integral part of these condensed consolidated financial statements. 4 ENGENE HOLDINGS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (AMOUNTS IN THOUSANDS

View Full Filing

View this 10-Q filing on SEC EDGAR